Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    empulse
Previous Study | Return to List | Next Study

A Study to Test the Effect of Empagliflozin in Patients Who Are in Hospital for Acute Heart Failure

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04157751
Recruitment Status : Completed
First Posted : November 8, 2019
Results First Posted : June 6, 2022
Last Update Posted : June 6, 2022
Sponsor:
Collaborator:
Eli Lilly and Company
Information provided by (Responsible Party):
Boehringer Ingelheim

Brief Summary:

This is a study in adults who are in hospital for acute heart failure. The purpose of this study is to find out whether starting to take a medicine called empagliflozin soon after first being treated in hospital helps people with acute heart failure.

Participants are in the study for about 3 months. At the beginning, participants are still in hospital. Later, they visit the hospital about 3 times and get 1 phone call. Participants are put into 2 groups by chance. One group takes 1 empagliflozin tablet a day. The other group takes

1 placebo tablet a day. Placebo tablets look like empagliflozin tablets but do not contain any medicine. Empagliflozin belongs to a class of medicines known as SGLT-2 inhibitors. It is used to treat type 2 diabetes.

During the study, the doctors check whether participants have additional heart failure events like needing to go to the hospital again because of heart failure. The participants answer questions about how their heart failure affects their life. We then compare the results between the empagliflozin and placebo groups. The doctors also regularly check the general health of the participants.


Condition or disease Intervention/treatment Phase
Heart Failure Drug: Empagliflozin Drug: Placebo to Empagliflozin Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 530 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Multicentre, Randomised, Double-blind, 90-day Superiority Trial to Evaluate the Effect on Clinical Benefit, Safety and Tolerability of Once Daily Oral EMPagliflozin 10 mg Compared to Placebo, Initiated in Patients Hospitalised for acUte Heart faiLure (de Novo or Decompensated Chronic HF) Who Have Been StabilisEd (EMPULSE)
Actual Study Start Date : May 18, 2020
Actual Primary Completion Date : May 28, 2021
Actual Study Completion Date : June 2, 2021


Arm Intervention/treatment
Experimental: Empagliflozin Drug: Empagliflozin
Film-coated tablet

Placebo Comparator: Placebo Drug: Placebo to Empagliflozin
Film-coated tablet




Primary Outcome Measures :
  1. Clinical Benefit, a Composite of Death, Number of Heart Failure Events (HFEs), Time to the First HFE and ≥5-point Difference in Change From Baseline in KCCQ-TSS After 90 Days of Treatment [ Time Frame: Up to 90 days. For KCCQ-TSS: at baseline and at day 90. ]

    Win ratio (WR) is a method for providing an estimate of the treatment effect when composite endpoints are analyzed as the analysis accounts for clinical significance of outcomes of interest in a hierarchical manner. Pairwise comparisons of each patient in the empagliflozin (empa) group with each patient in the placebo (pbo) group were performed within strata. The hierarchical sequence was stopped once an advantage for a patient was shown. Stratified win ratio was used, calculated as total number of wins in the empa group across all strata divided by total number of losses. Weights were applied analogous to a Mantel-Haenszel approach.

    WR estimate= [((a)+(c)+(e)+(g)) / ((b)+(d)+(f)+(h))];

    1. death in pbo first;
    2. death in empa first;
    3. HFEs in pbo more frequently;
    4. HFEs in empa more frequently;
    5. HFEs in pbo first;
    6. HFEs in empa first;
    7. KCCQ-TSS change lower in pbo;(h) KCCQ-TSS change lower in empa; KCCQ-TSS: Kansas City Cardiomyopathy Questionnaire-Total Symptom Score


Secondary Outcome Measures :
  1. Number of Participants With Improvement of at Least 10 Points in KCCQ-TSS After 90 Days of Treatment [ Time Frame: At baseline and at day 90. ]

    Number of participants with improvement of at least 10 points in Kansas City Cardiomyopathy Questionnaire - Total Symptom Score (KCCQ-TSS) from baseline after 90 days of treatment.

    The Kansas City Cardiomyopathy Questionnaire is a self-administered questionnaire that includes 23 items that map to 7 domains: symptom frequency, symptom burden, symptom stability, physical limitations, social limitations, quality of life and self-efficacy. The symptom frequency and symptom burden domains are merged into the total symptom score. Scores are represented on a 0-to-100-point scale, where a higher score reflects a better health status.


  2. Change From Baseline in KCCQ-TSS After 90 Days of Treatment [ Time Frame: At baseline, at day 15, 30 and at day 90. ]

    Change from baseline in Kansas City Cardiomyopathy Questionnaire - Total Symptom Score (KCCQ-TSS).

    The Kansas City Cardiomyopathy Questionnaire is a self-administered questionnaire that includes 23 items that map to 7 domains: symptom frequency, symptom burden, symptom stability, physical limitations, social limitations, quality of life and self-efficacy. The symptom frequency and symptom burden domains are merged into the total symptom score. The score is represented on a 0-to-100-point scale, where a higher score reflects a better health status.

    Change from baseline in KCCQ-TSS at day 90 was modeled using a MMRM with visit (day 15 and day 30) as repeated measures, adjusted mean (standard error) after 90 days of treatment is reported.


  3. Change From Baseline in Log-transformed N-Terminal Pro-Brain Natriuretic Peptide (NTproBNP) Area Under the Curve (AUC) Over 30 Days of Treatment [ Time Frame: From baseline to day 30. ]
    Change from baseline in log-transformed N-Terminal Pro-Brain Natriuretic Peptide (NTproBNP) Area under the curve (AUC) over 30 days of treatment is reported.

  4. Percentage of Days Alive and Out of Hospital (DAOH) From Study Drug Initiation Until 30 Days After Initial Hospital Discharge [ Time Frame: Up to 30 days after initial hospital discharge. ]

    The follow-up time for DAOH analyses was defined as 30 days after initial hospital discharge, or time between initial hospital discharge and date of censoring for non-fatal events except for patients who died within the first 30 days, where 30 days was considered as the DAOH follow-up time.

    DAOH for each patient was calculated as follow-up time subtracted by the number of days in hospital during the 30 days after initial hospital discharge as well as the number of days being dead within the 30 days. Percentage DAOH was defined as DAOH divided by the DAOH follow-up time of each patient multiplied by 100.


  5. Percentage of Days Alive and Out of Hospital (DAOH) From Study Drug Initiation Until 90 Days After Randomisation [ Time Frame: Up to 90 days after randomisation. ]

    The follow-up time for DAOH analyses was defined as 90 days after randomisation, or time between randomisation and date of censoring for non-fatal events except for patients who died within the first 90 days, where 90 days was considered as the DAOH follow-up time. DAOH for each patient was calculated as follow-up time subtracted by the number of days in hospital during the 90 days after randomisation as well as the number of days being dead within the first 90 days.

    Percentage DAOH was defined as DAOH divided by the DAOH follow-up time of each patient multiplied by 100.


  6. Incidence Rate of First Occurrence of Cardiovascular (CV) Death or Heart Failure Event (HFE) Until End of Trial Visit [ Time Frame: Up to 127 days. ]

    Incidence rate of first occurrence of CV death or HFE until end of trial visit per 100 patient-year (pt-yrs) at risk is reported.

    Incidence rate per 100 pt-yrs = 100* number of patients with event / time at risk [years].


  7. Number of Participants With Hospitalization for Heart Failure (HHF) Until 30 Days After Initial Hospital Discharge [ Time Frame: Up to 30 days after initial hospital discharge. ]
    Number of participants with hospitalization for heart failure (HHF) until 30 days after initial hospital discharge.

  8. Composite Renal Endpoint: Number of Participants With Chronic Dialysis, Renal Transplant, Sustained Reduction in eGFR(CKD-EPI)cr [ Time Frame: Up to 90 days. ]

    The occurrence of the composite renal endpoint:

    • chronic dialysis (with a frequency of twice per week or more for at least 90 days), or
    • renal transplant, or
    • sustained reduction in Glomerular filtration rate estimated by the chronic kidney disease epidemiology collaboration formula with serum creatinine measurement (eGFR (CKD-EPI)cr) from baseline of ≥40%, or
    • sustained eGFR [mL/min/1.73 m2] <15 and baseline value ≥30, or
    • sustained eGFR <10 and baseline value <30; is reported by number of participants with component events. (These events may have occurred after the endpoint was already met. Combinations may not have occurred on the same day).

    Sustained was determined by 2 or more consecutive post-baseline central laboratory measurements separated by at least 30 days.


  9. Weight Change Per Mean Daily Loop Diuretic Dose After 15 Days of Treatment [ Time Frame: At baseline and at day 15. ]

    Diuretic effect as assessed by weight change per mean daily loop diuretic dose after 15 days of treatment.

    Diuretic dose = 40 mg intravenous furosemide or 80 mg oral furosemide.

    Abbreviation:

    Kg: Kilogram


  10. Weight Change Per Mean Daily Loop Diuretic Dose After 30 Days of Treatment [ Time Frame: At baseline and at day 30. ]

    Diuretic effect as assessed by weight change per mean daily loop diuretic dose after 30 days of treatment.

    Diuretic dose = 40 mg intravenous furosemide or 80 mg oral furosemide

    Abbreviation:

    Kg: Kilogram




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Currently hospitalised for the primary diagnosis of acute heart failure (de novo or decompensated chronic HF), regardless of ejection fraction (EF). Patients with a diagnosis of hospitalized heart failure must have HF symptoms at the time of hospital admission
  • Evidence of left ventricular ejection fraction (LVEF, either reduced or preserved EF) as per local reading preferably measured during current hospitalisation or in the 12 months prior to randomisation
  • Patients must be randomised after at least 24 hours and no later than 5 days after admission, as early as possible after stabilization and while still in hospital
  • Patients must fulfil the following stabilisation criteria (while in the hospital):

    • SBP ≥100mm Hg and no symptoms of hypotension in the preceding 6 hours,
    • no increase in i.v. diuretic dose for 6 hours prior to randomisation,
    • no i.v. vasodilators including nitrates within the last 6 hours prior to randomisation
    • no i.v. inotropic drugs for 24 hours prior to randomisation.
  • Elevated NT-proBNP ≥ 1600pg/mL or BNP ≥400 pg/mL according to the local lab, for patients without atrial fibrillation (AF); or elevated NT-proBNP ≥ 2400pg/mL or BNP ≥600 pg/mL for patients with AF, measured during the current hospitalization or in the 72 hours prior to hospital admission,. For patients treated with an angiotensin receptor neprilysin inhibitor (ARNI) in the previous 4 weeks prior to randomisation, only NT-proBNP values should be used
  • HF episode leading to hospitalisation must have been treated with a minimum single dose of 40 mg of i.v. furosemide (or equivalent i.v. loop diuretic defined as 20 mg of torasemide or 1 mg of bumetanide)
  • Further Inclusion Criteria Apply

Exclusion Criteria:

  • Cardiogenic shock
  • Current hospitalisation for acute heart failure primarily triggered by pulmonary embolism, cerebrovascular accident, or acute myocardial infarction (AMI)
  • Current hospitalisation for acute heart failure not caused primarily by intravascular volume overload;
  • Below interventions in the past 30 days prior to randomisation or planned during the study:

    • Major cardiac surgery, or TAVI (Transcatheter Aortic Valve Implantation), or PCI, or Mitraclip
    • All other surgeries that are considered major according to investigator judgement
    • Implantation of cardiac resynchronisation therapy (CRT) device
    • cardiac mechanical support implantation
    • Carotid artery disease revascularisation (stent or surgery)
  • Acute coronary syndrome / myocardial infarction, stroke or transient ischemic attack (TIA) in the past 90 days prior to randomisation
  • Heart transplant recipient, or listed for heart transplant with expectation to receive a transplant during the course of this trial (according to investigator judgement), or planned for palliative care for HF, or currently using left ventricular assist device (LVAD) or intra-aortic balloon pump (IABP) or any other type of mechanical circulatory support, or patients on mechanical ventilation, or patients with planned inotropic support in an outpatient setting
  • Haemodynamically significant (severe) uncorrected primary cardiac valvular disease planned for surgery or intervention during the course of the study (note: secondary mitral regurgitation or tricuspid regurgitation due to dilated cardiomyopathy is not excluded unless planned for surgery or intervention during the course of the study)
  • Impaired renal function, defined as eGFR < 20 mL/min/1.73 m2 as measured during hospitalization (latest local lab measurement before randomisation) or requiring dialysis
  • Type 1 Diabetes Mellitus (T1DM)
  • History of ketoacidosis, including diabetic ketoacidosis (DKA)
  • Further Exclusion Criteria Apply

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04157751


Locations
Show Show 118 study locations
Sponsors and Collaborators
Boehringer Ingelheim
Eli Lilly and Company
  Study Documents (Full-Text)

Documents provided by Boehringer Ingelheim:
Study Protocol  [PDF] June 4, 2020
Statistical Analysis Plan  [PDF] March 11, 2021

Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT04157751    
Other Study ID Numbers: 1245-0204
2019-002946-19 ( EudraCT Number )
First Posted: November 8, 2019    Key Record Dates
Results First Posted: June 6, 2022
Last Update Posted: June 6, 2022
Last Verified: May 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description:

After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement".

Also, Researchers can use the following link https://www.mystudywindow.com/msw/datasharing to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.

The data shared are the raw clinical study data sets.

Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Clinical Study Report (CSR)
Time Frame: After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.
Access Criteria: For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.
URL: https://www.mystudywindow.com/msw/datasharing

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Failure
Heart Diseases
Cardiovascular Diseases
Empagliflozin
Sodium-Glucose Transporter 2 Inhibitors
Molecular Mechanisms of Pharmacological Action
Hypoglycemic Agents
Physiological Effects of Drugs